BIOAGE LABS INC (BIOA) Stock Price, Forecast & Analysis
NASDAQ:BIOA • US09077V1008
BIOA Key Statistics, Chart & Performance
The current stock price of BIOA is 20.46 USD. In the past month the price increased by 1.79%. In the past year, price increased by 349.67%.
BIOA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BIOA. When comparing the yearly performance of all stocks, BIOA is one of the better performing stocks in the market, outperforming 98.93% of all stocks.
BIOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIOA. While BIOA has a great health rating, there are worries on its profitability.
BIOA Financial Highlights
Over the last trailing twelve months BIOA reported a non-GAAP Earnings per Share(EPS) of -3.49. The EPS decreased by -6.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.84% | ||
| ROE | -27.32% | ||
| Debt/Equity | 0 |
BIOA Forecast & Estimates
11 analysts have analysed BIOA and the average price target is 30.6 USD. This implies a price increase of 49.56% is expected in the next year compared to the current price of 20.46.
BIOA Ownership
BIOA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.02 | 962.369B | ||
| JNJ | JOHNSON & JOHNSON | 21.18 | 598.856B | ||
| MRK | MERCK & CO. INC. | 22.15 | 301.342B | ||
| PFE | PFIZER INC | 8.85 | 154.992B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.06 | 126.909B | ||
| ZTS | ZOETIS INC | 18.34 | 56.831B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.15 | 27.402B | ||
| VTRS | VIATRIS INC | 5.94 | 18.077B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.65 | 12.971B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.51B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIOA
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Company Info
BIOAGE LABS INC
5885 Hollis Street, Suite 370
Emeryville CALIFORNIA H3B 4W8 US
CEO: Fabrice Orecchioni
Employees: 62
Phone: 15108061445
BIOAGE LABS INC / BIOA FAQ
What does BIOAGE LABS INC do?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Can you provide the latest stock price for BIOAGE LABS INC?
The current stock price of BIOA is 20.46 USD. The price decreased by -5.76% in the last trading session.
What is the dividend status of BIOAGE LABS INC?
BIOA does not pay a dividend.
What is the ChartMill rating of BIOAGE LABS INC stock?
BIOA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BIOAGE LABS INC (BIOA) stock traded?
BIOA stock is listed on the Nasdaq exchange.
Should I buy BIOA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIOA.
Can you provide the ownership details for BIOA stock?
You can find the ownership structure of BIOAGE LABS INC (BIOA) on the Ownership tab.